Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00280618
Status:
COMPLETED
Last Update Posted:
2009-09-15
First Post:
2006-01-20
Brief Title:
Oxaliplatin in Unresectable Hepatocellular Carcinoma
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Phase II Study of Eloxatin 5-FluorouracilLeucovorin in Patients With Unresectable Hepatocellular Carcinoma
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary
To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin5-FluorouracilLeucovorin
Secondary
Safety and tolerability of this regimen in these patients
To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin5-FluorouracilLeucovorin
Secondary
Safety and tolerability of this regimen in these patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None